Press release
Synovial Sarcoma Clinical Trial 2026 Gains Significant Traction as 15+ Pharma Innovators Advance 20+ Therapies | DelveInsight
Synovial Sarcoma Clinical Trial
Discover the newest advancements in Synovial Sarcoma research and explore our evolving therapeutic pipeline today: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Major Highlights from the Synovial Sarcoma Pipeline Report
• In February 2026, Takara Bio Inc. announced results of a Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
• In February 2026, Advenchen Laboratories announced results of a study that evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
• In January 2026, Immatics US, Inc announced results of a First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)
• In January 2026, Takara Bio Inc. commenced a clinical study evaluating the safety and efficacy of TBI-1301 in patients with NY-ESO-1-positive synovial sarcoma following cyclophosphamide/fludarabine conditioning therapy.
• DelveInsight's findings indicate a dynamic and competitive environment, with over 15 companies collectively developing more than 20 innovative therapies for synovial sarcoma.
• Prominent companies advancing Synovial Sarcoma therapies include Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, and PharmaMar, among others.
• Noteworthy pipeline candidates include TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib (in combination with Dacarbazine), Soblidotin, Doxorubicin, APX005M, Pazopanib, and additional emerging agents.
Stay updated on the latest progress in synovial sarcoma therapeutics and download the report for comprehensive insights: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Synovial Sarcoma Drug Profiles
AL3818: Advenchen Laboratories
AL3818 (Anlotinib) is an orally administered, next-generation receptor tyrosine kinase inhibitor targeting VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. By inhibiting angiogenesis and tumor proliferation pathways, it has demonstrated promising efficacy and an acceptable safety profile across multiple malignancies, including thyroid, renal, gastric, and esophageal cancers. The therapy is currently undergoing Phase III clinical evaluation for synovial sarcoma treatment.
Tazemetostat: Ipsen
Tazemetostat is an innovative oral small-molecule inhibitor targeting the epigenetic regulator EZH2, a histone methyltransferase involved in cancer progression. By selectively inhibiting EZH2, the drug aims to suppress tumor growth through gene expression modulation. In Japan, Eisai received approval in 2021 for relapsed or refractory EZH2 mutation-positive follicular lymphoma where standard therapies are unsuitable. Presently, Tazemetostat is in Phase II development for synovial sarcoma.
DS-2243a: Daiichi Sankyo
Daiichi Sankyo is developing DS-2243a, a bispecific T-cell engager (BiTE) designed to target HLA-A2 and NY-ESO antigens commonly expressed in synovial sarcoma cells. By bridging tumor antigens with cytotoxic T cells, this investigational therapy seeks to enhance immune-mediated tumor destruction. The ongoing Phase I study is assessing its safety, tolerability, and early efficacy signals in patients with advanced-stage synovial sarcoma who have limited treatment alternatives.
Insights Covered in the Synovial Sarcoma Pipeline Report
• Comprehensive evaluation of companies developing therapies for synovial sarcoma, including their cumulative drug portfolios.
• Categorization of therapeutic candidates into early-, mid-, and late-stage clinical development.
• Overview of both active and inactive research programs in targeted therapeutic development.
• Analysis of pipeline drugs segmented by development phase, route of administration, molecular target, monotherapy versus combination approach, mechanism of action, and molecular structure.
• Detailed assessment of strategic collaborations, licensing arrangements, and funding initiatives driving market expansion.
Explore therapeutic opportunities and innovations within our advanced research programs: https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Route of Administration (ROA) Classification
Pipeline candidates are categorized by delivery methods, including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type Classification
Synovial Sarcoma therapies are further segmented into:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Stay connected to see how oncology innovation continues to reshape the future of cancer care:
https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Report
• Global coverage
• Key companies: Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar, and others
• Key therapies: TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib combinations, Soblidotin, Doxorubicin, APX005M, Pazopanib, and more
• Therapeutic classification by mono, combination, and mono/combination therapies
• Clinical stage segmentation: Discovery, Preclinical, Phase I, Phase II, Phase III
For a comprehensive understanding of pipeline dynamics, market drivers, unmet needs, and analyst perspectives, access the full report on our website @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synovial Sarcoma Clinical Trial 2026 Gains Significant Traction as 15+ Pharma Innovators Advance 20+ Therapies | DelveInsight here
News-ID: 4405105 • Views: …
More Releases from DelveInsight Business Research
Adult T-Cell Leukemia-Lymphoma Market Forecast 2034: 7MM Analysis, 15+ Companies …
Prominent Adult T-Cell Leukemia-Lymphoma companies operating in the market include Daiichi Sankyo Co., Ltd., Kyowa Kirin, Inc., HUYABIO International, LLC., Celgene, Yale University, CRISPR Therapeutics, Bristol-Myers Squibb, Dren Bio, TCR2 Therapeutics, Janssen Research & Development, and PharmaMar, among others.
DelveInsight's "Adult T-Cell Leukemia-Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" publication delivers a comprehensive evaluation of Adult T-Cell Leukemia-Lymphoma (ATLL), encompassing both historical and projected epidemiological patterns along with detailed market trends…
Anti-CD19 Antibody Pipeline 2026: FDA Approvals and Clinical Trials Landscape wi …
According to DelveInsight, the global Anti-CD19 Antibody pipeline includes more than 12 prominent companies actively advancing over 12 therapeutic candidates. The analysis encompasses clinical trial progress, therapeutic strategies, mechanisms of action (MOA), routes of administration (ROA), and recent developments.
The report titled "Anti-CD19 Antibody Pipeline Insight, 2026" by DelveInsight provides a detailed overview of the current clinical landscape and future growth opportunities within the Anti-CD19 Antibody market.
The Anti-CD19 Antibody Pipeline report…
Gastroparesis Clinical Trial 2026: 6+ Companies, 8+ Emerging Therapies, and Key …
DelveInsight Business Research LLP has released its latest publication, "Gastroparesis Pipeline Insight, 2026," delivering in-depth analysis of 6+ companies and 6+ investigational drugs shaping the Gastroparesis treatment landscape. The report presents comprehensive profiles of pipeline candidates across clinical and preclinical stages. It also evaluates therapies by product category, development phase, route of administration, and molecular classification, while outlining discontinued and dormant programs within the space.
Stay informed with the most recent…
Aplastic Anemia Clinical Research Advances Rapidly: 5+ Innovators Drive Next-Gen …
DelveInsight's report, "Aplastic Anemia - Pipeline Insight, 2026" delivers an extensive evaluation of more than five companies and over eight investigational therapies shaping the aplastic anemia pipeline. The study outlines detailed drug profiles across clinical and preclinical stages, along with assessments based on product classification, development phase, route of administration, and molecular category. The report also sheds light on discontinued and inactive candidates within this therapeutic area.
Download DelveInsight's comprehensive Aplastic…
More Releases for Synovial
Synovial Sarcoma Market Projected to Reach USD 420 Million by 2034
Synovial sarcoma (SS) is a rare and aggressive form of soft tissue sarcoma, most commonly affecting adolescents and young adults. Though it accounts for only 5-10% of all soft tissue sarcomas, its rarity and severity make it a significant focus of rare cancer research. The disease is characterized by its chromosomal translocation (t(X;18)) and its tendency to metastasize, primarily to the lungs, creating challenges in long-term patient survival.
Download Full PDF…
Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an…
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Synovial…
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development.
Synovial Sarcoma: Introduction
Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to…
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,…
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size…
